|
GH Research PLC (GHRS) DCF -Bewertung
IE | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
GH Research PLC (GHRS) Bundle
Unser (GHRS) DCF-Taschenrechner (GHRS) für die Genauigkeit ermöglicht es Ihnen, die Bewertung der GH Research PLC anhand von Finanzdaten mit realen Welt zu bewerten, und bietet vollständige Flexibilität, um alle wesentlichen Parameter für verbesserte Prognosen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | -15.1 | -30.6 | -41.2 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .3 | .4 | .0 | .0 | .3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -.3 | -.4 | -15.1 | -30.7 | -41.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | .5 | 5.9 | 276.8 | 166.0 | 161.6 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .1 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | 3.0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .1 | .0 | .9 | 1.9 | 3.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | -.1 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -.3 | -.4 | -15.1 | -9.7 | -41.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .1 | -.1 | -17.4 | -5.7 | -39.8 | -3.3 | .0 | .0 | .0 | .0 |
| WACC, % | 8.59 | 8.59 | 8.59 | 8.5 | 8.59 | 8.57 | 8.57 | 8.57 | 8.57 | 8.57 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | -77 | |||||||||
| Equity Value | 74 | |||||||||
| Diluted Shares Outstanding, MM | 52 | |||||||||
| Equity Value Per Share | 1.43 |
What You Will Receive
- Authentic GHRS Financial Data: Pre-loaded with GH Research PLC’s historical and forecasted data for accurate analysis.
- Completely Customizable Template: Easily adjust essential inputs such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Observe GH Research PLC’s intrinsic value refresh in real-time as you make adjustments.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF outcomes.
- Intuitive Design: Clear layout and straightforward instructions suitable for all skill levels.
Key Features
- Comprehensive GHRS Financials: Gain access to reliable pre-loaded historical data and future forecasts.
- Adjustable Forecast Parameters: Modify highlighted cells for WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to help visualize your valuation findings.
- Designed for All Skill Levels: A straightforward, intuitive layout tailored for investors, CFOs, and consultants alike.
How It Works
- 1. Access the Template: Download and open the Excel file featuring GH Research PLC’s (GHRS) preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. View Results Immediately: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to assess different valuation results.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making process.
Why Choose This Calculator for GH Research PLC (GHRS)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust assumptions effortlessly to suit your evaluation needs.
- Real-Time Feedback: Observe immediate updates to GH Research’s valuation as you modify parameters.
- Pre-Loaded Data: Comes with GH Research’s actual financial metrics for swift assessments.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use GH Research PLC (GHRS)?
- Investors: Evaluate GH Research’s market position before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methods and assess financial forecasts.
- Startup Founders: Gain insights into how biotech companies like GH Research are valued.
- Consultants: Provide comprehensive valuation analyses for clients in the healthcare sector.
- Students and Educators: Utilize real-world examples to learn and teach valuation strategies in finance.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled GH Research PLC historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for GH Research PLC (GHRS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.